← Back to patent-cliff list
SYHX-1901
Tier C — Watch / tradeSYHX-1901
CSPC Ouyi Pharmaceutical Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Syk, TYK2
Indications (approved)：Vitiligo, Plaque psoriasis, Alopecia areata, Drug-related adverse effects and reactions, Psoriasis, Solid tumour, Haematological malignancy, Rheumatoid arthritis
Regional status
US
-
EU
-
China
Phase III
2025-06-12
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SYHX-1901?
Approved indications include: Vitiligo, Plaque psoriasis, Alopecia areata, Drug-related adverse effects and reactions, Psoriasis, Solid tumour, Haematological malignancy, Rheumatoid arthritis.
When does the SYHX-1901 patent expire?
No public expiry year is available for SYHX-1901 yet; this page updates once verified.
How do I get a quote for SYHX-1901 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30